特一藥業(002728.SZ):近期公司退燒類藥物銷售有所增長,但相關藥品屬於化學制劑藥,毛利率不高
格隆匯10月25日丨特一藥業(002728.SZ)於2023年10月24日接受投資者調研,就“公司退燒、感冒類藥品的增長情況?”,公司回覆稱,公司的對乙酰氨基酚片、布洛芬片、雙氯芬酸鈉腸溶片、感冒靈顆粒、複方氨酚烷胺膠囊適用於發熱、感冒症狀。近期,公司退燒類藥物銷售有所增長,但由於上述藥品均屬於化學制劑藥,毛利率不高,對公司經營業績及利潤貢獻沒有重大的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.